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Background & Aims: Primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC) and autoimmune hepatitis (AIH)
are phenotypically distinct autoimmune liver diseases that progress to cirrhosis and liver failure; however, their histological
fibrosis distribution differs. We investigated the extracellular matrix (ECM) profiles of patients with PSC, PBC, and AIH to
establish whether the diseases display differential patterns of ECM turnover.
Methods: Serum samples were retrospectively collected from the UK (test cohort; PSC n = 78; PBC n = 74; AIH n = 58) and
Norway (validation cohort; PSC n = 138; PBC n = 28; AIH n = 27). Patients with ulcerative colitis without liver disease (n = 194)
served as controls. We assessed specific serological biomarkers of ECM turnover: type III and V collagen formation (PRO-C3,
PRO-C5), degradation of type III and IV collagen (C3M, C4M), biglycan (BGM) and citrullinated vimentin (VICM).
Results: Most of the ECM markers showed elevated serum levels in PBC compared with PSC or AIH (p <0.01). PRO-C3
correlated well with liver stiffness and showed the most striking differences between advanced and non-advanced liver
disease; several of the other ECM markers were also associated with stage. PRO-C3 and other ECM markers were inversely
associated with ursodeoxycholic acid treatment response in PBC and remission in AIH. All ECM remodelling markers were
significantly elevated (p <0.05) in patients with PSC, PBC, or AIH compared with ulcerative colitis.
Conclusions: In this first study comparing ECM turnover in autoimmune liver diseases, we found increased ECM turnover in
PBC compared with either PSC or AIH. The study indicates that ECM remodelling is different in PSC, PBC, and AIH, suggesting
differing opportunities for therapeutic intervention.
© 2020 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL). This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The autoimmune liver diseases primary biliary cholangitis (PBC),
primary sclerosing cholangitis (PSC) and autoimmune hepatitis
(AIH) share scientific and clinical challenges. In PSC, an incom-
plete comprehension of the pathogenesis and a lack of validated
tools to evaluate effect of novel treatment, have hindered the
development of improved therapy. Currently, PBC patients are
treated with ursodeoxycholic acid which successfully halts dis-
ease progression in the majority whereas a substantial group ofKeywords: Biomarker; Fibrosis; Primary sclerosing cholangitis; Primary biliary
cholangitis; PRO-C3.
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progress; AIH patients receive immune modulating therapy
which induces remission in the majority but maintain a 10 times
increased risk of progression to liver transplantation or death
compared with the general population. Thus, a substantial
number of patients with each of the 3 diseases progress to
cirrhosis and liver failure and, although each is rare, collectively,
they represent an important indication for liver transplantation.
A better comprehension of the pathways driving each individual
disease might facilitate the successful development of highly
warranted effective therapies.1–3
Biomarkers of fibrosis have demonstrated utility in the pre-
diction of prognosis in a spectrum of chronic liver diseases,
including the autoimmune liver diseases, PBC, PSC, and AIH.
Histological liver fibrosis stage was demonstrated to predict
clinical outcomes but is currently not recommended in standard
Research articlediagnostics in PBC and PSC.4,5 Non-invasive markers of fibrosis
offer better opportunity for repeated assessments over time and
have been reported as effective risk stratifiers for clinical out-
comes. In PBC and PSC, independently validated biomarkers
include the enhanced liver fibrosis (ELF) test, a serum marker
panel, and liver stiffness measurement (LSM) using transient
elastography (TE; Fibroscan, Echosens, Paris, France).6–10 How-
ever, these tools, developed for chronic liver diseases in general,
are usually considered as measures of fibrosis load and may not
capture the diversity in fibrosis distribution and progression rate
between the autoimmune liver diseases reflecting differences in
pathogenesis, nor the dynamic process of fibrogenesis and
fibrosis degradation and remodelling (reflecting disease activity)
at any given stage of fibrosis. Serological biomarkers specifically
targeting the extracellular matrix (ECM) remodelling may better
assess these variations and dynamics.
We hypothesised that valuable additional information about
the dynamics of fibrosis evolution in autoimmune liver disease
would be provided by estimating the ECM turnover profile using
serological biomarkers specifically targeting the ECM remodel-
ling, differentiating between the formation and degradation
processes related to the various compartments (the interstitial
matrix and the basement membrane). New knowledge regarding
the differences in pathogenesis underlying PSC and the other
autoimmune liver diseases could indicate differing opportunities
for therapeutic intervention. Furthermore, a dynamic evaluation
of the disease activity using specific markers of ECM turnover
could lead to the identification of sensitive biomarkers for dis-
ease monitoring and assessment of treatment response in ther-
apeutic trials, responding to an unmet need for surrogates for
clinical events particularly in PSC.11
We have previously shown that the marker of type III collagen
formation (PRO-C3) is a strong predictor of prognosis in PSC.12 In
this study, we explored several serological biomarkers specif-
ically targeting ECM remodelling. Many of these have been
demonstrated to be related to various chronic liver diseases as
either diagnostic,13–15 prognostic,16,17 or surrogate efficacy
markers.18,19 These markers specifically target the end-product of
tissue remodelling, that is a neo-epitope resulting from a specific
protein cleaved by a specific protease, which is released into the
circulation and may serve as biomarker for that pathological
process. Combining both the protease and the protein may better
assess the dynamic activity of a disease state, compared with
other biomarkers targeting the intact protein. Using this tech-
nique, we investigated the ECM turnover profile of patients with
PSC compared with PBC and AIH in 2 independent cohorts to
evaluate associations with liver stiffness and disease stage for
each disease and to establish whether differential patterns of
ECM turnover are seen between the diseases.Materials and methods
Patient panels
We adopted a 2-step study design (Fig. S1). We explored char-
acteristics of ECM turnover in a test panel consisting of PSC pa-
tients compared with PBC and AIH patients (n = 80, 76, and 57,
respectively) prospectively recruited at the Royal Free Hospital,
UK, then validated main findings in a previously described in-
dependent validation panel of Norwegian PSC patients (n = 138)
compared with PBC and AIH patients (n = 28 and 27, respec-
tively), all retrospectively collected from the NoPSC Biobank,JHEP Reports 2021Norway. Characteristics of the study population are shown in
Table 1. Diagnosis of PSC was based on typical cholangiographic
findings according to acknowledged criteria; the first patholog-
ical cholangiography defined the time of diagnosis of PSC.20 PBC
and AIH were diagnosed based on acknowledged criteria.3,20
Duration of disease was defined as the time from the date of
diagnosis to the date of serum sampling. Cases of PSC or PBC
with features of AIH were included in the PSC and PBC patient
panels, respectively (Table 1). Cases of secondary cholangitis or
small duct PSC were excluded. Control sera from 194 patients
with ulcerative colitis (UC) where PSC had been excluded (all had
normal cholangiograms by magnetic resonance cholangiography
and normal alkaline phosphatase [ALP]) were retrieved for
comparison from the 20-year follow-up visit of a population-
based Norwegian cohort.21 All patients provided informed
consent in writing. The protocol was in accordance with the
Declaration of Helsinki and approved by the regional committee
for research ethics in southeastern Norway (ref. 2011/2572) and
the UK.
For the test panel patients and the validation panel PSC pa-
tients, the respective research databases were revised for infor-
mation on clinical and laboratory data, including ascites,
encephalopathy, oesophageal varices, variceal bleeding, inflam-
matory bowel disease (IBD) status, and colorectal or hep-
atobiliary malignancy at the time of serum extraction. An IBD
diagnosis was based on findings at colonoscopy and histology.
Diagnosis of UC and Crohn’s disease were established by
accepted criteria.
For the test cohort, advanced liver disease was defined based
on LSMs using published cut-off values for TE in PSC and PBC8,9
and LSMs or histology in AIH. PBC response was defined ac-
cording to the Toronto criteria (ALP <1.67 xULN) at 24 months.
AIH remission was defined according to published criteria as
normalisation of IgG and alanine aminotransferase (ALT). For the
PBC and AIH validation and IBD control panels, limited pheno-
typic information was available. Liver stiffness was not available
for the validation panel.
Biochemical analyses were performed using standard routine
laboratory protocols for tests including platelets, creatinine, in-
ternational normalised ratio (INR), aspartate aminotransferase
(AST), ALT, ALP, and gamma-glutamyltransferase (GGT). The AST
to platelet index (APRI) and PSC-specific revised Mayo risk score
were calculated using the published algorithms.22,23
The date of serum sample extraction was identical for the
frozen sera used for analyses of biomarkers of ECM turnover and
the ELF test, and routine laboratory biochemical analyses,
respectively, in all cases of PSC in the validation panel and in all
but 6 cases in the test panel (n = 2 for each of the 3 diseases).Biomarkers of ECM turnover
We used validated competitive ELISAs (Nordic Bioscience, Herlev,
Denmark) to assess true formation of interstitial matrix collagen
PRO-C3 and type V (PRO-C5), degradation of interstitial matrix
collagen type III (C3M) and basement membrane type IV
collagen (C4M), degradation of the proteoglycan biglycan (BGM)
and citrullinated type III intermediate filament protein vimentin
(VICM), in serum samples from all of the patients in each patient
panel. All biomarkers were assessed in a blinded manner ac-
cording to the manufacturer24–29 and samples were measured
within the detection range.2vol. 3 j 100178
Table 1. Baseline characteristics.
Test panel Validation panel Controls
PSC PBC AIH p value* PSC PBC AIH p value† UC
N 80 76 57 138 28 27 194
Males, n (%) 54 (67.5) 7 (9.2) 9 (15.8) <0.001 107 (77.5) 4 (13.8) 11 (40.7) <0.001
Age, years, median (range) 46 (20–80) 60 (29–83) 51 (21–76) <0.001 60 (16–72) 60 (31–72) 43 (19–81)
Age at diagnosis, years,
median (range)
36 (16–80) 49 (29–78) 43 (11–70) <0.001 34 (14–72) n.a. n.a. – n.a.
Disease duration, years,
median (range)
5 (0–28) 7 (0–22) 6 (0–47) n.s. 1.7 (–0.6–29) n.a. n.a. – n.a.
Features of AIH, n (%) 7 3 n.a. <0.001 11 1 n.a. <0.001 n.a.
IBD ever, n (%) 56 (70.0) 1 (1.3) 3 (5.2) <0.001 102 (74.4) n.a. n.a. – 194
UC, n (% of all) 49 (61.3) 0 (0) 1 (1.8) <0.001 81 (59.1) n.a. n.a. – 194
(100)
Colorectal malignancy, n (%) 1 0 0 n.s. 5 n.a. n.a. – n.a.
Hepatobiliary malignancy, n (%) 1 1 0 n.s. 1 n.a. n.a. – n.a.
Liver transplantation, n (%) 6 1 0 0.025 31 n.a. n.a. – n.a.
Death, n (%) 2 1 0 n.s. 16 n.a. n.a. – n.a.
Time-follow-up, years,
median (range)
0.4 (0–1.5) 0.6 (-0.1–1.5) 0.7 (0–1.8) n.s. 0.5 (0–4.2) n.a. n.a. – n.a.
Disease stage measures
LSM, kPa, median (range) 10.3 (2.5–75.0) 7.7 (3.0–37.4) 6.9 (2.6–75.0) n.s. n.a. n.a. n.a. –I n.a.
Advanced disease, n (%) 30 (38.0)#
41 (53.9)‡
27 (38.0) 18 (33.3) 0.05§ (<0.02)§§ 68 (52.7)#
ELF score, median (range) 10.1 (7.3–14.3) 10.1 (8.3–12.4) 9.9 (9.4–10.3) n.s. 9.7 (7.1–15.7) n.a. n.a. – n.a.
APRI score, median (range) 0.5 (0.1–10.4) 0.4 (0.09–4.9) 0.3 (0.1–25.3) 0.030 0.5 (0.1–23.7) n.a. n.a. – n.a.
Mayo risk score,
median (range)




49/30 n.a. n.a. NI 61/68 n.a. n.a. – n.a.
Laboratory values
ALP, U/L median (range) 198 (21–807) 173 (49–959) 85 (34–218) <0.001 224 (51–1459) n.a. n.a. – n.a.
AST, U/L median (range) 50 (16–919) 43 (17–318) 27 (10–1437) <0.001 68 (16–1219) n.a. n.a. – n.a.
ALT, U/L median (range) 48 (9–796) 48 (11–472) 28 (9–519) <0.001 85 (14–885) n.a. n.a. – n.a.
Albumin, g/L median (range) 44 (21–807) 44 (30–50) 44 (23–53) n.s. 41 (23–50) n.a. n.a. – n.a.
Total bilirubin, lmol/L
median (range)
13 (3–274) 8 (2–330) 9 (3–124) <0.001 20 (3–532) n.a. n.a. – n.a.
INR, median (range) 1 (0.7–3.8) 1 (0.8–1.4) 1 (0.9–2.1) <0.001 1 (0.8–1.8) n.a. n.a. – n.a.
Platelet count, 109/L
median (range)
244 (53–536) 259 (83–658) 225 (44–480) 0.044 248 (22–903) n.a. n.a. – n.a.
Creatinine, median (range) 74 (45–138) 70 (43–166) 68 (43–100) 0.043 65 (37–111) n.a. n.a. – n.a.
GGT, median (range) 186 (13–1594) 116 (27–818) 33 (8–324) <0.001 248 (22–1620) n.a. n.a. – n.a.
* The p-value represents comparison between PSC, PBC, and AIH within the test panel.
† The p-value represents comparison between PSC, PBC, and AIH within the validation panel.
‡ Defined by LSM using the published cut-off value for F3: n = 41 (53.9%); §PSC (LSM) vs. PBC; §§PSC (LSM) vs. AIH.
# Defined by Mayo score. The Mann-Whitney U test was used for comparisons between continuous non-normally distributed parameters; Student t test was used when
appropriate. AIH, autoimmune hepatitis; ALP, alkaline phosphatase; ALT, alanine transferase; APRI, AST to platelet ratio index; AST, aspartate transferase; ELF, enhanced liverELF test
We analysed frozen serum samples from the PSC patients using
the commercially available ELF test (Siemens Medical Solution
Diagnostics, Inc., Tarrytown, NY, USA). The assays for analysis of
serum levels of tissue inhibitor of metalloproteinase-1 (TIMP-1),
hyaluronic acid (HA) and intact N-terminal procollagen type III
(PIIINP) were performed using the Siemens ELF test kits con-
taining assays designed specifically for the purpose of generating
the ELF test and an ADVIA Centaur XP analyser (Siemens Medical
Solutions Diagnostics, Inc.).Liver stiffness measurements
Prospectively collected LSMs using TE for the assessment of liver
fibrosis were available for n = 211 patients in the test panel. LSMs
were performed at median 0 month from the time of biobanking
in each diagnostic group (>6 months for n = 5, 4 and 2 patients
with PSC, PBC, and AIH, respectively).JHEP Reports 2021Statistical analyses
We tested continuous variables for normal distribution and
applied the Student t test or the Mann-Whitney U test as
appropriate. The collagen III turnover was calculated as PRO-C3/
C3M. We calculated the PSC-specific Mayo risk score for the PSC
patients and categorised these patients into low- (<−0), medium-
(>0 to <−2) and high- (>2) risk groups using published cut-off
values. Data are presented as median (range). We explored cor-
relations between the novel ECM markers and continuous vari-
ables using Spearman’s rank test. For calculation of 95%
confidence intervals of rho, the Fisher r-to-z transformation was
used {tanh[arctanh(r) ± 1.96/sqrt(n - 3)]}. Advanced liver disease
was defined based on published cut-off values; in PSC by LSMs
(>−F3; PSC: >9.6 kPa; test panel) or Mayo risk score >0 (both
panels), in PBC and AIH by LSMs (>−F3; 10.7 and >10.4 kPa,
respectively).8,9,30 In addition, we defined advanced disease as
APRI score >1 for secondary analyses (Supplementary material).
The power of ECM biomarkers and the ELF test to discriminate3vol. 3 j 100178
Research articlebetween patients with and without advanced disease was eval-
uated by the area under the receiver operating characteristics
curve (AUROC) analysis; differences between AUROCs were
compared with the method of DeLong.31 Optimal cut-off values
to discriminate between patients were obtained from the AUROC
analysis according to the Youden index. We explored associa-
tions between clinical and laboratory variables and advanced
disease by univariate logistic regression analysis. ECM markers
were not normally distributed and therefore normalised to ter-
tiles before analyses; non-normally distributed standard labo-
ratory tests (thrombocytes) were transformed by the natural
logarithm. AUROCs are presented with 95% confidence interval
(CI). Values of p <0.05 were considered significant. Statistical
analyses were performed using MedCalc (Statistical Software
version 16.8.4, MedCalc Software bvba, Ostend, Belgium) and
SPSS (version 24, SPSS Inc., Chicago, IL, USA). Graphs were
designed using GraphPad Prism version 8.1.2 (GraphPad Soft-
ware, La Jolla, CA, USA).
Data availability
Data are available upon request and an appropriate institutional
collaboration agreement.Results
Patients
Patient characteristics are shown in Table 1. We included a test
panel of 78 PSC patients, 74 PBC patients, and 58 AIH patients as
well as an independent validation panel of 138 PSC patients, 28
PBC patients, and 27 AIH patients. Patients with UC with normal
bile duct imaging by magnetic resonance cholangiography (n =
194) served as controls. The test and validation liver disease
panels were similar for each aetiology as regards median age,
gender distribution (except for a higher male proportion in the
AIH validation panel), the proportion of IBD in PSC patients, and
the proportion of PSC or PBC patients with features of AIH.
However, as expected, gender distribution was not equal
across diagnostic groups, with a male majority amongst PSC
patients and a strong female predominance for PBC patients
(males: 67.5, 9.2, and 15.8% in PSC, PBC, and AIH, respectively;
p <0.001). PBC patients were older compared with PSC (median
age 60 vs. 45 years; p <0.001) and median age at diagnosis
differed between the 3 diagnoses (Table 1). Overall, 70.0% vs.
74.4% of PSC patients had IBD in the test and validation panels,
with UC affecting 61.3% and 59.1%, respectively. Comorbidity
with IBD was lower in PBC and AIH patients (Table 1). In the test
panel, 36 (69.2%) PBC patients were documented ursodeox-
ycholic acid responders and 24 AIH patients (46.2%) were in
remission.
There was no significant difference in the proportion of pa-
tients with advanced disease between PSC and PBC patients
within the test panel (53.9% vs. 38.0% in PSC and PBC, respec-
tively; p = 0.053), whereas in AIH patients there was a proportion
with advanced disease (33.3%) which was similar to PBC
(p = 0.59) but lower compared with PSC (p <0.02). Disease
duration was similar between patients with PSC, PBC, and AIH
(median duration [years]: 5 [0–28], 7 [0–22] and 6 [0–47],
respectively; p = 0.60). Furthermore, there were no significant
differences between PSC and PBC patients regarding markers
related to stage including LSMs (10.3 [2.5–75.0] vs. 7.7 [3.0–37.4],
respectively; p = 0.09), APRI score (0.62 [0.15–12.65] vs. 0.53
[0.13–7.07]; p = 0.43) or, in subsets (n = 45), ELF test (10.1JHEP Reports 2021[7.3–14.3] vs. 10.1 [8.3–12.4], respectively; p = 0.87) (Table 1).
Information regarding disease stage was not available for PBC or
AIH for the validation panel.
Comparing PSC test and validation panels, patients showed
similar ELF tests (test panel: n = 45; 10.1 [7.3–14.3] and 9.7
[7.2–15.7], respectively, p = 0.66) and APRI scores (p = 0.22)
indicating similar levels of fibrosis; whereas the Mayo score was
higher and disease duration shorter in the validation panel
compared with the test panel (Mayo score: median [range] -0.3
[-2.3–3,7] and 0.1 [-2.4–4.1], p = 0.009; duration: p <0.001).
Biomarkers of ECM remodelling in PBC, PSC, and AIH
compared with UC controls
A majority of ECM markers, including PRO-C3, PRO-C5, C3M,
C4M, and BGM, showed an overall difference in serum levels
between PSC, PBC, and AIH in both test and validation panels (p
<0.01, Fig. 1). Interestingly, the ECM turnover was overall higher
in PBC compared with the other autoimmune liver diseases.
PRO-C5, C3M, C4M, and BGM were significantly higher (p <0.05
to p <0.001) in PBC sera compared with PSC as well as AIH in the
2 independent panels (Fig. 1). Concerning PRO-C3, findings
indicated elevated levels in PBC compared with PSC or AIH but
were inconsistent between the panels (Fig. 1). None of the other
markers showed any consistent significant differences between
liver aetiologies. All ECM remodelling markers were significantly
elevated (p <0.05) in patients with PSC compared with UC con-
trols in both the test and validation panels (Fig. 1).
The ratio between formation and degradation of type III
collagen, that is PRO-C3/C3M is shown in Fig. S2. The ratio was
elevated in PSC as compared with PBC and AIH in the test panel;
however, no differences between aetiologies were found in the
validation panel, although there was a trend towards higher ratio
in PBC as compared with PSC and AIH. In both panels, the ratio
was significantly increased as compared with UC controls.
Associations of the ECM markers with liver disease stage
We explored whether the levels of the ECM markers were
different between patients with non-advanced vs. advanced
disease (see Materials and methods section for definitions).
Several ECM markers showed elevated levels in advanced dis-
ease, with the most striking differences between advanced and
non-advanced disease for PRO-C3 for all aetiologies (percent
reduction in non-advanced compared with advanced disease:
68%, 56%, and 39% in PSC, PBC, and AIH, respectively) (Table 2),
underscoring an important association of collagen III formation
with advanced disease for all 3 autoimmune liver diseases.
In PSC, elevated levels of PRO-C3 and PRO-C3/C3M ratio
(reflecting the balance between collagen III formation and
degradation) were observed in advanced compared with non-
advanced disease (Table 2), whereas no significant difference
was demonstrated for the other markers. In multivariate logistic
regression analyses including age, sex, disease duration, ALP,
Mayo risk score, and a single ECM marker at a time, we
demonstrated independent association with advanced PSC for
PRO-C3 as the single variable in the final model (5.57 [2.38,
13.05], p <0.001). No independent association was found for
other ECM markers. To compare findings in the test and valida-
tion panels, we further defined advanced compared with
non-advanced disease using the Mayo score, confirming the
associations for PRO-C3 and PRO-C3/C3M ratio with advanced
PSC. Furthermore, these analyses showed significantly elevated
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Fig. 1. ECM markers in patients with PSC, PBC, AIH and UC. Levels of all ECM remodelling markers were higher in all 3 autoimmune liver diseases compared
with UC controls. PBC patients showed higher levels of most ECM markers compared with PSC and AIH. (A) PRO-C3 (marker of type III collagen formation), (B)
PRO-C5 (marker of type V collagen formation), (C) C3M (marker of type III collagen degradation), (D) C4M (marker of type IV collagen degradation), (E) BGM
(marker of biglycan degradation), and (F) VICM (marker of citrullinated vimentin degradation). Comparisons made using the Student t test; asterisks indicate
statistical significances p <0.05. Differences within test and validation panels are indicated by *; differences between test and validation panel are indicated by ¤;
differences between ulcerative colitis (UC) controls and test panel are indicated by $; differences between UC controls and validation panel are indicated by #.
AIH, autoimmune hepatitis; ECM, extracellular matrix; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis; UC, ulcerative colitis.In PBC and AIH, PRO-C3, C3M, and C4M (in both PBC and AIH)
and PRO-C3/C3M ratio and BGM (in PBC), showed significantly
elevated levels in advanced compared with non-advanced dis-
ease whereas VICM showed lower values in advanced PBC as
well as AIH (Table 2). Multivariate analysis as above but
substituting bilirubin and ursodeoxycholic acid response for the
Mayo score showed strong and independent association with
advanced PBC for PRO-C3 (12.05, 95% CI [2.89, 50.20], p = 0.001)
and PRO-C3/C3M ratio (4.33, 95% CI [1.51, 12.40], p = 0.006). In
AIH, multivariate analyses including sex, AIH duration, remission
state and 1 ECM marker at a time showed independent associ-
ation only for PRO-C3 (3.49 [1.17, 10.45], p = 0.03).
We performed AUROC analyses of the ability of the ECM
markers to detect advanced disease in PSC, PBC, and AIH,
respectively (Table 3). Overall, PRO-C3 performed best, showing
excellent (AUC >0.8; in PSC and PBC) or good (AUC = 0.771; AIH)
ability to discriminate advanced from non-advanced disease.
Furthermore, in PSC, PRO-C3, and PRO-C3/C3M ratio discrimi-
nated well (AUC >0.7) between mild and advanced disease as
defined by the Mayo score in both panels, whereas discrimina-
tory ability was also demonstrated for PRO-C5, C3M, and C4M in
both panels with AUC >0.6, and for BGM (AUC >0.6) in the vali-
dation panel only (Table 4). In PBC and AIH, PRO-C5, C3M, and
C4M (both aetiologies) and VICM and BGM (in PBC) discrimi-
nated between advanced and non-advanced disease (Table 3).
Correlations between the ECM markers and LSMs, fibrosis
scores and Mayo risk score.
PRO-C3 showed the strongest correlation with established
fibrosis markers compared with the other ECM markers for anyJHEP Reports 2021of the aetiologies. In PSC, PRO-C3 displayed strong correlation
with LSMs (rho >0.5, p <0.001) and excellent correlation with ELF
test (validation panel; rho 0.83, p <0.001; Table 4). C3M (both
panels) and C4M (validation panel only) also showed significant
correlations with LSMs in PSC, linking collagen degradation to
liver stiffness in PSC (Table 4). Supporting an association with
fibrosis in PSC, in the validation panel, these markers as well as
PRO-C5 showed significant correlations with ELF test, a well-
established fibrosis marker panel associated with prognosis in
PSC. No correlation with either LSMs or ELF test was seen for
BGM and VICM (Table 4). Finally, in PSC, PRO-C3 correlated well
with the Mayo risk score in both PSC panels (rho 0.59 and 0.70,
respectively; p <0.001). PRO-C5, C3M, and C4M were also
correlated with the Mayo risk score in both panels (Table 4).
In PBC and AIH, PRO-C3 showed good correlation with LSMs
(rho = 0.56 and 0.48, respectively; both p <0.001). Correlations
with LSMs were also demonstrated for C3M, C4M, and VICM for
PBC as well as AIH (Table 4).
Associations of the ECM markers with disease activity in PBC
and AIH
Several ECM markers were reduced in PBC patients who were
ursodeoxycholic acid responders (n = 36; 69.2%) compared with
non-responders (n = 16; 30.8%) (Fig. 2). Responders showed
reduced levels for PRO-C3 (median 37.3 vs. 18.6; p = 0.002), PRO-
C5 (1650.3 vs. 1096.3; 0.001), C3M (26.8 vs. 14.1; p <0.001), C4M
(58.8 vs. 31.6; p <0.001), and BGM (26.7 vs. 18.8; p = 0.04). In
addition, increased levels were found in responders for VICM
(4.7 vs. 9.7; p <0.001). There was no difference for LSMs (median





















































































































































































































































































































































































































































































































































































































































































































































































JHEP Reports 2021In patients with AIH with available data (n = 52), ECM
markers PRO-C5, C3M, and C4M showed reduced levels in pa-
tients in remission (n = 24; 46.2%) compared with non-remission
(n = 28; 53.8%) with reduced values in remission for PRO-C5,
C3M, and C4M (median 1114.0 vs. 724.2; 14.6 vs. 10.3; 31.9 vs.
24.7; p = 0.001, 0.001 and 0.002, respectively) (Fig. 3) whereas no
difference across disease activity state was demonstrated for
BGM, VICM, or LSMs.Outcome prediction
We have previously reported that markers of collagen formation
(PRO-C3, PRO-C5) and degradation (C3M, C4M) are associated
with prognosis in PSC.12 Extending analyses to BGM and VICM,
AUROC analyses showed modest discriminatory ability for BGM
to discriminate between PSC patients who did and did not reach
liver transplantation or death during follow-up (AUC 0.63; p =
0.02), relating biglycan degradation to clinical outcome in PSC for
the first time. Survival times were reduced in high-risk vs. low-
risk groups (defined by optimal cut-off values as decided by
Youden) for BGM (mean survival 1.80 vs. 2.87 [p = 0.009];
Table S1). BGM (hazard ratio 2.34, p = 0.012) was associated with
reaching the clinical endpoint in univariate Cox-regression
analysis (Table S2). Low event-rate and short follow-up in the
test panel and missing outcome data for validation panel PBC
and AIH patients precluded analysis for these panels.Discussion
In this study, we have dissected the ECM remodelling in 3
autoimmune liver diseases using highly specific, targeted
markers reflecting the dynamic balance between fibrogenesis
and fibrosis degradation in the liver. For the first time, we
demonstrate a striking difference in ECM remodelling indicating
higher turnover in PBC compared with either PSC or AIH. This
difference could not be explained by differences in stage, as the
proportion of patients with advanced liver disease was not
different between PBC and the other autoimmune liver diseases.
Our results highlight the differences between the 3 diseases as
regards fibrosis composition and handling, underscore the
pathogenetic differences between PSC and PBC, and clearly
establish PBC as a high-turnover disease compared with PSC and
AIH.
The difference that we observed between PBC and PSC sup-
ports the notion that, despite the fact that PBC and PSC both give
rise to biliary-type fibrosis as evidenced by histology, the path-
ogenesis leading to this result may be fundamentally different
between the 2 diseases. Whereas the fibrogenesis in PSC is
mainly driven by pro-fibrogenic factors derived from ‘reactive’
cholangiocytes, in PBC, the fibrogenesis is driven by a more
defined immune-mediated inflammation and characterised by
ECM degradation associated with cholangiocyte damage. Hence,
portal fibrosis in PBC is more similar to a chronic wound healing
reaction, which could explain the higher ECM turnover
compared with PSC. In AIH, fibrogenesis is initiated in the liver
lobule instead of the portal tract; hence, different pro-fibrogenic
cells are likely involved. In addition, the ratio between formation
and degradation of type III collagenwas significantly increased in
all aetiologies as compared with UC controls, further suggesting
not only an increased turnover of type III collagen, but also an
increased net deposition of type III collagen in all aetiologies
compared with UC.6vol. 3 j 100178
Table 3. AUROC analyses of the discriminatory ability of extracellular matrix markers for detecting advanced disease.
Test panel Validation panel
PSC PBC AIH PSC PSC
LSM* LSM* LSM* Mayo Mayo










































































































* For analyses involving LSM: panel restricted to patients with LSM available and AST <175. Published cut-off levels for fibrosis (F3) were used (PSC >9.6 kPa, PBC >10.7 kPa;
AIH >10.4 kPa). Mayo risk score cut-off 0 differentiated mild vs. moderate-high risk. Values are given as AUC (95% CI). AIH, autoimmune hepatitis; AUROC, area under the
receiver operator characteristics curve; BGM, biglycan marker; ELF, enhanced liver fibrosis test; LSM, liver stiffness measurement; Mayo, PSC-specific revised Mayo risk score;
PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis; VICM, citrullinated vimentin.We demonstrated the association of several of the novel
markers with fibrosis in autoimmune liver diseases, showing
increased levels of markers of collagen formation as well as
degradation, underscoring that the fibrosis in autoimmune liver
diseases represents a relatively high-turnover condition, as an





































































* Analysis restricted to patients with AST <175. Correlations were explored using Spearm
degradation of biglycan; C3M, degradation of type III collagen; C4M, degradation of type
PSC-specific revised Mayo risk score; PBC, primary biliary cholangitis; PRO-C3 and P
cholangitis; VICM, degradation of citrullinated vimentin.
JHEP Reports 2021in osteoporosis.32 This suggests that therapeutic strategies aimed
at altering the balance between fibrosis formation and degra-
dation may benefit patients.
PRO-C3 showed the strongest association with fibrosis of
the ECM markers, as underscored by the tight (in PSC and PBC)
or moderate (in AIH) correlation of PRO-C3 with LSMs andliver fibrosis or prognosis.
Validation panel
Mayo ELF Mayo
AIH PSC PSC PSC





















































































an’s rank test. AIH, autoimmune hepatitis; BGM, matrix metalloproteinase mediated
IV collagen; ELF, enhanced liver fibrosis test; LSM, liver stiffness measurement; Mayo,
RO-C5, formation of type III and V collagen, respectively; PSC, primary sclerosing














































































Non-responders Responders Non-responders Responders Non-responders Responders
Non-responders Responders Non-responders Responders
Fig. 2. Extracellular matrix markers are different dependent on disease activity in patients with primary biliary cholangitis. The boxplots show significantly
lower levels of extracellular matrix markers in patients with PBC who were ursodeoxycholic acid responders (n = 36) compared with non-responders (n = 16) for
(A) type III collagen formation (PRO-C3; p = 0.002), (B) type V collagen formation (PRO-C5; p = 0.001), (C) C3M (p <0.001), (D) C4M (p <0.001), (E) biglycan (BGM;
p <0.05), and increased level for (F) citrullinated vimentin (VICM; p <0.001). * p <− 0.05; ** p <0.005; *** p <− 0.001. PBC, primary biliary cholangitis.
Research articleserum-based fibrosis scores such as the ELF test and APRI score.
We demonstrated the presence of higher levels in advanced dis-
ease for PRO-C3 for all aetiologies. Overall, PRO-C3 showed the
most consistent difference between stages in autoimmune liver
disease. In line with this, PRO-C3 performed best for stage
discrimination, with good to excellent ability to discriminate
advanced from non-advanced disease in PSC as well as PBC
and AIH.
Of the other markers, collagen degradation markers C3M and






















































Fig. 3. Extracellular matrix markers are different dependent on disease activ
matrix markers in patients with autoimmune hepatitis in remission (n = 24) comp
collagen formation (PRO-C5), (C) degradation of type III collagen (C3M), (D) de
vimentin (VICM). Levels were significantly lower in patients with remission for P
JHEP Reports 2021fibrosis, including correlations to LSMs and ELF test, presence of
higher levels in advanced compared with non-advanced disease
(in PBC and AIH) and good performance for stage discrimination
in PBC and AIH but not in PSC. Interestingly, this points to a
possible role for destruction of the basement membrane, which
type IV collagen is the main component of, in the pathogenesis of
the autoimmune liver diseases. Moreover, the associations be-
tween these diseases and a BGM are of interest because biglycan
is an important TGF-beta binding protein that releases TGF-beta


























on Remission Non-remission Remission
on Remission Non-remission Remission
ity in patients with autoimmune hepatitis. The boxplots show extracellular
ared with non-remission for (A) type III collagen formation (PRO-C3), (B) type V
gradation of type IV collagen (C4M), (E) biglycan (BGM) and (F) citrullinated
RO-C5, C3M and C4M (p = 0.001). *** p <− 0.001.
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observations should lead to further exploration of biglycan as a
therapeutic target.
Thus, our study confirms increased ECM remodelling in
advanced compared with non-advanced disease as previously
reported for other liver diseases.16,18,25 Stage definition and
evaluation of the level of fibrosis is not straightforward in PSC
and PBC as liver biopsy is not routinely performed and because
the patchy distribution of fibrosis may affect the reliability of
histology. Hence, we defined advanced disease based on disease-
specific cut-off values for moderate fibrosis (F3) for LSMs by TE,
for which the association with histological stage and clinical
outcome has been validated in independent studies in PBC as
well as PSC.8,9 Furthermore, to compare test and validation
panels in PSC, we defined disease severity groups using the PSC-
specific Mayo risk score, which is the most commonly used
predictive tool in PSC although not validated at the individual
level.22 We believe that the evaluation of the ECM markers
against several measures of disease stage or severity, including
LSMs, strengthens our analysis; however, independent validation
of the associations between the ECM markers and LSMs in larger
disease-specific patient panels is warranted. Conceivably, ECM
marker analysis may allow improved stage distinction in PSC as
well as PBC compared with LSMs, given that serum markers
better reflect the status of the whole organ compared with the
limited assessment by LSMs which may not be representative in
diseases with patchy distribution such as PSC and PBC; however,
the present study does not allow any conclusions in this regards.
Our demonstration of excellent correlation of PRO-C3 with
LSMs and serum scores of fibrosis and the strong ability to
discriminate between advanced and non-advanced disease,
support the association of PRO-C3 with stage as a marker of
prognosis and hence our previous report showing strong pre-
dictive ability of PRO-C3 in PSC.12 PRO-C3 is a marker of forma-
tion of collagen III, one of the most abundant collagens in liver
cirrhosis. In contrast, PIIINP which is used as a marker of liver
fibrosis alone or as part of the ELF test, reflects the total pool of
collagen III, including formation, degradation, and stable ver-
sions of the collagen. Potentially, this might yield improved
reflection of the dynamics of fibrogenesis to PRO-C3 as compared
with PIIINP or the ELF test.
We report higher levels of PRO-C3 and other ECM markers in
ursodeoxycholic acid non-responders compared with responders
for PBC and in patients with active disease compared with
remission for AIH, indicating an association of ECMmarkers with
disease activity in autoimmune liver diseases. Our findings are in
line with previous publications demonstrating that PRO-C3 is
associated with disease activity in HIV patients under treatment
for C3M and C4M;18 moreover, reduction in PRO-C3 levels as well
as the ELF test was reported following treatment in PSC with
NGM282, an FGF19 analogue, as a further indication that PRO-C3
levels may reflect disease activity.33 Interestingly, the serum
levels of the ECM markers observed in this study were muchJHEP Reports 2021higher compared with that previously found in other liver dis-
eases such as NAFLD.34,35 We speculate that this might be caused
by pro-fibrogenic effects of bile acids via activation of portal fi-
broblasts. In support of this, findings from NGM Bio show that
the change in bile acid concentration is positively correlated to
the change in PRO-C3 in patients with non-alcoholic steatohe-
patitis.36,37 Further studies in larger, disease-specific patient
panels are warranted to establish whether PRO-C3 is a good
candidate surrogate marker of disease activity in PBC and other
autoimmune liver diseases.
We have previously demonstrated excellent ability for PRO-
C3 to detect patients reaching a clinical endpoint during
follow-up in PSC, whereas PRO-C5 and C3M showed significant
but weaker outcome discriminatory abilities.12 The present
extension of the analysis to novel ECM markers relates biglycan
degradation to clinical outcome in PSC for the first time and
indicates a role for BGM for risk stratification in PSC, although
further studies are warranted.
The analysis of a broad panel of novel ECM markers in a
parallel design of patients with 3 different autoimmune liver
diseases and the validation in independent panels for each
aetiology represent strengths of the study. The number of pa-
tients differed between aetiologies (PSC > PBC or AIH) with
relatively small validation groups for PBC and AIH, and this
represents a limitation which may have affected power and
hence results. Stage definition was complicated by the lack of
liver biopsy; however, liver biopsy is not routinely indicated in
either PSC or PBC, furthermore we employed LSMs to define
stage in the majority of test panel patients. LSMs was not
available in Norway at the time of inclusion of patients in the
validation panel, but we were able to define stage in PSC vali-
dation patients using the Mayo risk score. The levels of several of
the ECM markers were different between the test and validation
panels with in general higher levels in the validation panel for
part or all of the aetiologies for a majority of the markers,
although all of the samples were analysed by the same protocol,
in the same batch and the same laboratory. We can only spec-
ulate that this might be related to differences in ethnicity of the
patients, with a purely Caucasian validation panel and a mixed-
ethnicity test panel. The short follow-up time and relatively few
events in the test panel precluded independent validation of
analyses regarding the predictive abilities of the ECM markers.
In this first comparison of ECM markers in autoimmune liver
diseases we found an overall increased ECM turnover in PBC
compared with either PSC or AIH, indicating that the ECM
remodelling is different in PSC, PBC, and AIH. This might suggest
differing opportunities for therapeutic intervention for patients
with PSC, PBC, and AIH; hence, further investigation of ECM
remodelling markers is warranted. Furthermore, we have
demonstrated for the first time the close and consistent associ-
ation of the ECM remodelling marker PRO-C3 with liver stiffness
and stage in PSC, PBC, and AIH, respectively.Abbreviations
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